If management are even 1/3rd right about the growth outlook for the AD trials market, Cogstate is going to become a cash generation machine. As they alluded to on the call they already have sufficient surplus cash to consider M&A opportunities and if they are unable to find a suitable target, they will consider returns to shareholders in 12 months or so's time.
CGS Price at posting:
$1.79 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)